The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

Since its discovery in 2011, CRISPR-Cas 9 has revolutionized medicine. One of the companies at the forefront of this ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

“We have demonstrated, for the first time worldwide, that CRISPR-Cas9 can be used to incorporate a desired sequence into ...

To this end, CRISPR Therapeutics is currently managing five other clinical trials, with several more pre-clinical studies ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) can’t seem to catch a break, now down close to 8% year to date and more than 80% ...

CRISPR Therapeutics (NasdaqGM:CRSP) recently announced its Q1 2025 earnings, reporting a 71% year-over-year revenue increase to $0.9 million, but also a wider net loss of $136 million. The basic and ...

Research on Toxoplasmosis reveals potential vaccine strategy targeting essential splicing protein, offering protection ...

The researchers have conducted a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique aimed at ...